Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SURMOUNT-1

SURMOUNT-1

Tirzepatide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Tirzepatide
Population
obesity
Official title
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2019-12 → 2022-04
Participants
2539
Duration
72 weeks
Registry
NCT04184622, NCT07481747

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
tirzepatide 5 mgobesity722539−16.0 % vs −2.4 %
Δ −13.6 pp
−15.0 % vs −3.1 %
Δ −11.9 pp
—4.3 vs 2.6—24.6 vs 9.58.3 vs 1.76.3 vs 6.8—verified
tirzepatide 10 mgobesity722539−21.4 % vs −2.4 %
Δ −19.0 pp
−19.5 % vs −3.1 %
Δ −16.4 pp
—7.1 vs 2.6—33.3 vs 9.510.7 vs 1.76.9 vs 6.8—verified
tirzepatide 15 mgobesity722539−22.5 % vs −2.4 %
Δ −20.1 pp
−20.9 % vs −3.1 %
Δ −17.8 pp
—6.2 vs 2.6—31.0 vs 9.512.2 vs 1.75.1 vs 6.8—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (18)
  • tirzepatide 5 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
    −16.0% (95% CI, −16.8 to −15.2), a weight reduction of 16.1 kg (35.5 lb), with the 5-mg dose
  • tirzepatide 5 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
    −15.0% (95% CI, −15.9 to −14.2) with a 5-mg weekly dose of tirzepatide
  • tirzepatide 5 mg · ae_dc · Results, Participants; Table 4 (27 [4.3])
    Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
  • tirzepatide 5 mg · nausea · Table 4, adverse events in at least 5% of participants
    Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
  • tirzepatide 5 mg · vomiting · Table 4, adverse events in at least 5% of participants
    Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
  • tirzepatide 5 mg · sae · Table 4
    Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
  • tirzepatide 10 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
    −21.4% (95% CI, −22.2 to −20.6), a reduction of 22.2 kg (48.9 lb), with the 10-mg dose
  • tirzepatide 10 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
    −19.5% (95% CI, −20.4 to −18.5) with a 10-mg dose
  • tirzepatide 10 mg · ae_dc · Results, Participants; Table 4 (45 [7.1])
    Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
  • tirzepatide 10 mg · nausea · Table 4, adverse events in at least 5% of participants
    Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
  • tirzepatide 10 mg · vomiting · Table 4, adverse events in at least 5% of participants
    Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
  • tirzepatide 10 mg · sae · Table 4
    Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
  • tirzepatide 15 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
    −22.5% (95% CI, −23.3 to −21.7), a reduction of 23.6 kg (52.0 lb) with the 15-mg dose
  • tirzepatide 15 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
    −20.9% (95% CI, −21.8 to −19.9) with a 15-mg dose
  • tirzepatide 15 mg · ae_dc · Results, Participants; Table 4 (39 [6.2])
    Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
  • tirzepatide 15 mg · nausea · Table 4, adverse events in at least 5% of participants
    Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
  • tirzepatide 15 mg · vomiting · Table 4, adverse events in at least 5% of participants
    Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
  • tirzepatide 15 mg · sae · Table 4
    Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)

Related registry entries

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
SURMOUNT-1
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
ObesityPhase 3recruiting2026-02 → 2027-022539recruitingNCT07481747
SURMOUNT-1
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
ObesityPhase 3completed2019-12 → 2022-042539Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT04184622

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SURMOUNT-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.